Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration and supply agreement with AbbVie Inc. and Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
IPO Year:
Exchange: NASDAQ
Website: iderapharma.com
Wedbush downgraded Idera Pharma from Outperform to Neutral and set a new price target of $1.00 from $8.00 previously
Barclays downgraded Idera Pharmaceuticals from Overweight to Equal-Weight and set a new price target of $2.00 from $10.00 previously
JMP Securities downgraded Idera Pharmaceuticals from Outperform to Market Perform
HC Wainwright & Co. downgraded Idera Pharmaceuticals from Buy to Neutral
JP Morgan downgraded Idera Pharmaceuticals from Overweight to Neutral